Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT103 in refractory hypercalcemia of malignancy
CTR20192472Phase 2Terminated
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of narlumosbart in cancer-associated hypercalcemia, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started May 2020; status: terminated.
02
Drugs
narlumosbart
03
Conditions
cancer-associated hypercalcemia
Beyond the preview
Go deeper on CTR20192472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192472.